Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Chemo Research S L currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are spread across 2 distinct art units, which indicates a focus on specific technical niches. The company is engaging with 3 distinct examiners for these cases.
Rajan Pragani is the busiest examiner for this portfolio, although he is responsible for 1 pending office action. Because there are 3 pending actions, the workload is distributed with each examiner handling a case. This lack of examiner concentration means that the company must manage separate examiner relationships simultaneously.
The 2 distinct art units involved suggest that the 3 pending office actions are grouped into different technical areas. With 3 distinct examiners, the company faces a variety of perspectives even within those art units. Practitioners should be prepared for diverse feedback across the active matters in the Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRAGANI, RAJAN | 1 | 53.3% | +70.0% |
| GHALI, ISIS A D | 1 | 27.9% | +41.6% |
| AZPURU, CARLOS A | 1 | 83.8% | +10.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605521 | METHOD AND DEVICE FOR PROVIDING EFFECTIVE CONTRACEPTION | GHALI, ISIS A D | 46d |
| 18682824 | METHOD FOR TREATING ENDOMETRIOSIS AND PROVIDING EFFECTIVE CONTRACEPTION | AZPURU, CARLOS A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605521 | METHOD AND DEVICE FOR PROVIDING EFFECTIVE CONTRACEPTION | GHALI, ISIS A D | 46d |
| 18842742 | CHEWABLE ORAL CONTRACEPTIVE | PRAGANI, RAJAN | — |
| 18682824 | METHOD FOR TREATING ENDOMETRIOSIS AND PROVIDING EFFECTIVE CONTRACEPTION | AZPURU, CARLOS A | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18842742 | CHEWABLE ORAL CONTRACEPTIVE | PRAGANI, RAJAN | — | §103DP | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18605521 | METHOD AND DEVICE FOR PROVIDING EFFECTIVE CONTRACEPTION | GHALI, ISIS A D | 1611 | §103 | Final Rejection | 46d | Pending | Mar 14, 2024 |
| 18682824 | METHOD FOR TREATING ENDOMETRIOSIS AND PROVIDING EFFECTIVE CONTRACEPTION | AZPURU, CARLOS A | 1617 | §103§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial